|
CZ295838B6
(cs)
*
|
1996-09-09 |
2005-11-16 |
Zealand Pharma A/S |
Způsob výroby peptidů
|
|
AU757658B2
(en)
|
1998-03-09 |
2003-02-27 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
SE9801571D0
(sv)
|
1998-05-05 |
1998-05-05 |
Wapharm Ab |
Melanokortin-1-receptorselektiva föreningar
|
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
AU765753B2
(en)
*
|
1999-05-17 |
2003-09-25 |
Conjuchem Biotechnologies Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
PT1180121E
(pt)
|
1999-05-17 |
2004-03-31 |
Conjuchem Inc |
Peptidos insulinotropicos de longa duracao
|
|
EP1076066A1
(en)
*
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US6890896B1
(en)
*
|
1999-11-18 |
2005-05-10 |
Ceremedix, Inc. |
Compositions and methods for counteracting effects of reactive oxygen species and free radicals
|
|
US6756480B2
(en)
|
2000-04-27 |
2004-06-29 |
Amgen Inc. |
Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
|
|
EP1294746B1
(en)
*
|
2000-06-16 |
2011-05-04 |
Serodus AS |
Peptide conjugates modified n- and/or c-terminally by short charged peptide chains
|
|
US7244701B2
(en)
|
2000-06-16 |
2007-07-17 |
Zealand Phama A/S |
Diuretic peptide conjugate
|
|
US7550425B2
(en)
|
2000-06-16 |
2009-06-23 |
Zealand Pharma A/S |
Diuretic peptide conjugates
|
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
PT1326630E
(pt)
|
2000-09-18 |
2008-09-02 |
Sanos Bioscience As |
Utilização de péptidos glp-2
|
|
WO2002038609A2
(en)
|
2000-11-10 |
2002-05-16 |
Proteopharma Aps |
Apolipoprotein conjugates
|
|
JP2006516947A
(ja)
*
|
2000-11-16 |
2006-07-13 |
ニュー リバー ファーマシューティカルズ インコーポレイテッド |
新規な医薬化合物およびその製造方法と使用方法
|
|
DK1360202T3
(da)
|
2001-02-16 |
2008-09-22 |
Conjuchem Biotechnologies Inc |
Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
|
|
EP1411968B1
(en)
|
2001-07-31 |
2008-09-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Glp-1 exendin-4 peptide analogs and uses thereof
|
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
|
JP2010229140A
(ja)
*
|
2002-02-22 |
2010-10-14 |
Shire Llc |
活性物質送達系及び活性物質を保護し投与する方法
|
|
US7666979B2
(en)
*
|
2002-03-01 |
2010-02-23 |
Bracco International B.V. |
Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
|
|
US8623822B2
(en)
|
2002-03-01 |
2014-01-07 |
Bracco Suisse Sa |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
|
US7261876B2
(en)
|
2002-03-01 |
2007-08-28 |
Bracco International Bv |
Multivalent constructs for therapeutic and diagnostic applications
|
|
WO2004065621A1
(en)
|
2002-03-01 |
2004-08-05 |
Dyax Corp. |
Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
|
|
US7211240B2
(en)
*
|
2002-03-01 |
2007-05-01 |
Bracco International B.V. |
Multivalent constructs for therapeutic and diagnostic applications
|
|
US7794693B2
(en)
|
2002-03-01 |
2010-09-14 |
Bracco International B.V. |
Targeting vector-phospholipid conjugates
|
|
WO2003090604A2
(en)
*
|
2002-04-24 |
2003-11-06 |
University Of Florida |
Method of endovascular brain mapping
|
|
US6881829B2
(en)
*
|
2002-04-26 |
2005-04-19 |
Chimeracom, L.L.C. |
Chimeric hybrid analgesics
|
|
MXPA04012497A
(es)
|
2002-07-04 |
2005-07-14 |
Zealand Pharma As |
Glp-1 y metodos para tratar la diabetes.
|
|
BR0314996A
(pt)
|
2002-10-02 |
2005-08-09 |
Zealand Pharma As |
Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
|
|
WO2004037859A1
(ja)
*
|
2002-10-11 |
2004-05-06 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Glp-1誘導体及びその経粘膜吸収型製剤
|
|
RU2005119978A
(ru)
*
|
2002-11-25 |
2006-01-27 |
Зилэнд Фарма А/С (Dk) |
Пептидные модуляторы щелевых контактов
|
|
US7648962B2
(en)
*
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
|
SG159387A1
(en)
*
|
2002-11-26 |
2010-03-30 |
Biocon Ltd In |
Modified natriuretic compounds, conjugates, and uses thereof
|
|
WO2004078777A2
(en)
*
|
2003-03-04 |
2004-09-16 |
Biorexis Pharmaceutical Corporation |
Dipeptidyl-peptidase protected proteins
|
|
GB0307777D0
(en)
|
2003-04-04 |
2003-05-07 |
Medical Res Council |
Conjugate compounds
|
|
WO2005063791A2
(en)
|
2003-12-31 |
2005-07-14 |
F. Hoffmann-La Roche Ag |
Process for peptide synthesis using a reduced amount of deprotection agent
|
|
EP2272524A3
(en)
|
2004-03-17 |
2011-02-02 |
7TM Pharma A/S |
Y2 selective receptor agonists for therapeutic interventions
|
|
DK2060266T3
(da)
|
2004-03-17 |
2011-11-14 |
7Tm Pharma As |
Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb
|
|
PL1759001T3
(pl)
|
2004-04-21 |
2011-09-30 |
Alexion Pharma Inc |
Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
|
|
ES2347902T3
(es)
|
2004-04-23 |
2010-11-22 |
Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 |
Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
|
|
US9006181B2
(en)
|
2004-07-21 |
2015-04-14 |
The Administrators Of The Tulane Educational Fund |
Treatment of renal dysfunction and multiple myeloma using PACAP compounds
|
|
JO2937B1
(en)
|
2004-08-11 |
2016-03-15 |
فيرينغ.بي.في |
Tight muscles of the peptide vascular tensioner receptor
|
|
CA2580796C
(en)
|
2004-09-24 |
2013-03-26 |
Amgen Inc. |
Modified fc molecules having peptides inserted in internal loop regions
|
|
ATE480561T1
(de)
|
2004-10-19 |
2010-09-15 |
Lonza Ag |
Verfahren zur festphasen-peptidsynthese
|
|
WO2006076471A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Nobex Corporation |
Bnp conjugates and methods of use
|
|
TWI376234B
(en)
|
2005-02-01 |
2012-11-11 |
Msd Oss Bv |
Conjugates of a polypeptide and an oligosaccharide
|
|
GB0505420D0
(en)
*
|
2005-03-16 |
2005-04-20 |
Isogenica Ltd |
Stable ligand selection method
|
|
WO2006097682A1
(en)
*
|
2005-03-18 |
2006-09-21 |
Ucl Business Plc |
Mechano growth factor peptides and their use
|
|
DE602006020123D1
(de)
|
2005-05-04 |
2011-03-31 |
Zealand Pharma As |
Glucagon-like-peptide-2- (glp-2-) analoga
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
ES2407107T3
(es)
|
2005-08-26 |
2013-06-11 |
Abbvie Inc. |
Análogos de alfa-MSH terapéuticamente activos
|
|
CN103497237B
(zh)
*
|
2005-08-26 |
2015-10-28 |
艾伯维有限公司 |
治疗活性的α-MSH类似物
|
|
US9333240B2
(en)
|
2005-09-16 |
2016-05-10 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Compounds for improving nutritional status, cognition and survival
|
|
EP1934245B1
(en)
*
|
2005-09-21 |
2011-07-13 |
7TM Pharma A/S |
Y2 selective receptor agonists for therapeutic interventions
|
|
CN101268099A
(zh)
*
|
2005-09-21 |
2008-09-17 |
7Tm制药联合股份有限公司 |
用于治疗性干预的y4选择性受体激动剂
|
|
RS51319B
(sr)
*
|
2005-09-22 |
2010-12-31 |
Biocompatibles Uk Limited |
GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
|
|
CA2913805A1
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
|
AU2006329215A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Conjuchem Biotechnologies Inc. |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
|
US8883965B2
(en)
|
2006-02-10 |
2014-11-11 |
Ferring B.V. |
Compounds
|
|
WO2007144768A2
(en)
*
|
2006-02-13 |
2007-12-21 |
Ferring B.V. |
Use of peptidic vasopressin receptor agonists
|
|
EP1854455B1
(en)
|
2006-05-10 |
2009-10-07 |
Biocompatibles UK Limited |
Spherical microcapsules comprising GLP-1 peptides, their production and use
|
|
US20100062986A1
(en)
*
|
2006-05-31 |
2010-03-11 |
Immuneregen Biosciences, Inc. |
Method to treat blood cell depletion
|
|
DK2046826T3
(da)
|
2006-07-24 |
2011-10-24 |
Biorexis Pharmaceutical Corp |
Exendin-fusionsproteiner
|
|
SI2084183T1
(sl)
|
2006-10-13 |
2010-09-30 |
Lilly Co Eli |
Pegilirani pth kot modulatorji pth receptorja in njihove uporabe
|
|
AU2007319066B2
(en)
|
2006-11-08 |
2013-09-19 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (GLP-2) analogues
|
|
EP1961765A1
(en)
*
|
2006-12-08 |
2008-08-27 |
Zealand Pharma A/S |
Truncated PTH peptides with a cyclic conformation
|
|
CN101578102B
(zh)
|
2007-01-05 |
2013-07-17 |
印第安纳大学研究及科技有限公司 |
在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
|
|
US8889632B2
(en)
|
2007-01-31 |
2014-11-18 |
Dana-Farber Cancer Institute, Inc. |
Stabilized p53 peptides and uses thereof
|
|
NZ578948A
(en)
|
2007-02-15 |
2012-03-30 |
Univ Indiana Res & Tech Corp |
Glucagon/glp-1 receptor co-agonists
|
|
EP2508531B1
(en)
|
2007-03-28 |
2016-10-19 |
President and Fellows of Harvard College |
Stitched polypeptides
|
|
WO2008152403A1
(en)
|
2007-06-15 |
2008-12-18 |
Zealand Pharma A/S |
Glucagon analogues
|
|
EP2175874A2
(en)
|
2007-08-14 |
2010-04-21 |
Ferring B.V. |
Use of peptidic vasopressin receptor agonists
|
|
KR20100059863A
(ko)
*
|
2007-09-11 |
2010-06-04 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서의 펩티드 티모신 베타 4 단독 또는 세크로핀 a와의 배합물의 용도
|
|
WO2009043468A2
(en)
*
|
2007-09-11 |
2009-04-09 |
Mondobiotech Laboratories Ag |
Use of corticotropin-releasing factor as a therapeutic agent
|
|
KR20100061481A
(ko)
*
|
2007-09-11 |
2010-06-07 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서의 미니가스트린
|
|
WO2009033667A2
(en)
*
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
|
CA2707861A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
|
WO2009058734A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
|
CN101951937A
(zh)
*
|
2007-12-21 |
2011-01-19 |
赫尔辛医疗股份公司 |
使用伊帕瑞林刺激胃肠系统动力的方法
|
|
US20110065633A1
(en)
|
2008-01-30 |
2011-03-17 |
Indiana University Research And Technology Corporation |
Ester-based peptide prodrugs
|
|
CA2728284C
(en)
|
2008-06-17 |
2019-09-10 |
Richard D. Dimarchi |
Glucagon/glp-1 receptor co-agonists
|
|
ES2558842T3
(es)
|
2008-06-17 |
2016-02-09 |
Indiana University Research And Technology Corporation |
Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
|
|
TWI541023B
(zh)
|
2008-06-17 |
2016-07-11 |
印第安納大學科技研究公司 |
在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
|
|
PT3228320T
(pt)
|
2008-10-17 |
2020-03-26 |
Sanofi Aventis Deutschland |
Combinação de uma insulina e de um agonista do glp-1
|
|
ES2502218T3
(es)
|
2008-12-15 |
2014-10-03 |
Zealand Pharma A/S |
Análogos de glucagón
|
|
US8642540B2
(en)
|
2008-12-15 |
2014-02-04 |
Zealand Pharma A/S |
Glucagon analogues
|
|
MA32970B1
(fr)
|
2008-12-15 |
2012-01-02 |
Zealand Pharma As |
Analogues du glucagon
|
|
AU2008365557A1
(en)
|
2008-12-15 |
2011-07-21 |
Zealand Pharma A/S |
Glucagon analogues
|
|
JP5789515B2
(ja)
|
2008-12-19 |
2015-10-07 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
インスリン類似体
|
|
EP2376097A4
(en)
|
2008-12-19 |
2012-10-03 |
Univ Indiana Res & Tech Corp |
PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
|
|
US8697632B2
(en)
|
2008-12-19 |
2014-04-15 |
Indiana University Research And Technology Corporation |
Amide based insulin prodrugs
|
|
WO2010148089A1
(en)
|
2009-06-16 |
2010-12-23 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
|
PH12011502708B1
(en)
|
2009-07-06 |
2017-11-10 |
Sanofi Aventis Deutschland |
Insulin preparations containing methionine
|
|
JP6054742B2
(ja)
|
2009-07-13 |
2016-12-27 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
|
DK2459183T3
(en)
|
2009-07-27 |
2016-01-18 |
Nocicepta Llc |
Methods for the treatment of pain
|
|
FR2948809B1
(fr)
*
|
2009-07-31 |
2012-08-17 |
St Microelectronics Rousset |
Amplificateur de lecture faible puissance auto-minute
|
|
JP5908406B2
(ja)
*
|
2009-11-02 |
2016-04-26 |
ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド |
下垂体アデニル酸シクラーゼ活性化ポリペプチド(pacap)の類似体およびその使用方法
|
|
SG10201500871TA
(en)
|
2009-11-13 |
2015-04-29 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
JP5832439B2
(ja)
|
2009-11-13 |
2015-12-16 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
|
|
WO2011075393A2
(en)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
WO2011088462A2
(en)
*
|
2010-01-18 |
2011-07-21 |
Albany Medical College |
Alpha-fetoprotein 'ring and tail' peptides
|
|
EP2525808A2
(en)
|
2010-01-19 |
2012-11-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
|
WO2011088837A1
(en)
|
2010-01-20 |
2011-07-28 |
Zealand Pharma A/S |
Treatment of cardiac conditions
|
|
KR20120123443A
(ko)
|
2010-01-27 |
2012-11-08 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트
|
|
CN103003300B
(zh)
|
2010-04-27 |
2017-06-09 |
西兰制药公司 |
Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
|
|
ES2661228T3
(es)
|
2010-05-13 |
2018-03-28 |
Indiana University Research And Technology Corporation |
Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
|
|
RU2012153753A
(ru)
|
2010-05-13 |
2014-06-20 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
|
|
JP5969469B2
(ja)
|
2010-06-16 |
2016-08-17 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
|
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
US8778872B2
(en)
|
2010-06-24 |
2014-07-15 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
CA2803164C
(en)
|
2010-06-24 |
2018-08-21 |
Indiana University Research And Technology Corporation |
Amide-based insulin prodrugs
|
|
CA2802897A1
(en)
|
2010-06-24 |
2011-12-29 |
Zealand Pharma A/S |
Glucagon analogues
|
|
SI2603600T1
(sl)
|
2010-08-13 |
2019-04-30 |
Aileron Therapeutics, Inc. |
Peptidomimetični makrocikli
|
|
CN103179978A
(zh)
|
2010-08-30 |
2013-06-26 |
赛诺菲-安万特德国有限公司 |
Ave0010用于制造供治疗2型糖尿病用的药物的用途
|
|
US8796416B1
(en)
|
2010-10-25 |
2014-08-05 |
Questcor Pharmaceuticals, Inc |
ACTH prophylactic treatment of renal disorders
|
|
NZ612297A
(en)
|
2010-12-22 |
2015-10-30 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting gip receptor activity
|
|
JP6055779B2
(ja)
|
2010-12-27 |
2016-12-27 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
ナトリウム利尿ペプチドを含む組成物およびその使用方法
|
|
EP2678002A2
(en)
|
2011-02-25 |
2014-01-01 |
Medtronic, Inc. |
Therapy for kidney disease and/or heart failure
|
|
EP3189835B1
(en)
*
|
2011-02-28 |
2018-07-25 |
National Cerebral and Cardiovascular Center |
Medical agent for suppressing malignant tumor metastasis
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
JP6184404B2
(ja)
|
2011-06-22 |
2017-08-23 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
グルカゴン/glp−1レセプターコアゴニスト
|
|
CN103857408B
(zh)
|
2011-06-22 |
2017-04-12 |
印第安那大学科技研究公司 |
胰高血糖素/glp‑1受体协同激动剂
|
|
JP6367115B2
(ja)
|
2011-08-29 |
2018-08-01 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病患者の血糖コントロールに使用する組合せ医薬
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
EP2750697A4
(en)
|
2011-09-02 |
2015-03-25 |
Medtronic Inc |
CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
|
|
JP6126097B2
(ja)
|
2011-09-06 |
2017-05-10 |
ノヴォ ノルディスク アー/エス |
Glp−1誘導体
|
|
TW201806968A
(zh)
|
2011-10-18 |
2018-03-01 |
艾利倫治療公司 |
擬肽巨環化合物
|
|
KR20140100947A
(ko)
|
2011-11-03 |
2014-08-18 |
질랜드 파마 에이/에스 |
Glp-1 수용체 효능제 펩타이드 가스트린 접합체들
|
|
BR112014007124A2
(pt)
|
2011-11-17 |
2017-06-13 |
Univ Indiana Res & Tech Corp |
superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
|
|
CN102504019B
(zh)
*
|
2011-12-01 |
2014-04-23 |
北京龙科方舟生物工程技术有限公司 |
一种分离天蚕素抗菌肽的方法
|
|
CN104114183A
(zh)
|
2011-12-20 |
2014-10-22 |
印第安纳大学研究及科技有限公司 |
用于治疗糖尿病的基于ctp的胰岛素类似物
|
|
KR20140114845A
(ko)
|
2011-12-23 |
2014-09-29 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
|
WO2013109610A1
(en)
*
|
2012-01-17 |
2013-07-25 |
Steven Hoffman |
Pharmaceutical compositions and methods
|
|
US10272068B2
(en)
|
2012-01-17 |
2019-04-30 |
Tyme, Inc. |
Pharmaceutical compositions and methods
|
|
US8481498B1
(en)
|
2012-01-17 |
2013-07-09 |
Steven Hoffman |
Pharmaceutical compositions and methods
|
|
US10646552B2
(en)
|
2012-01-17 |
2020-05-12 |
Tyme, Inc. |
Pharmaceutical compositions and methods
|
|
US20130183263A1
(en)
|
2012-01-17 |
2013-07-18 |
Steven Hoffman |
Pharmaceutical compositions and methods
|
|
HK1205454A1
(en)
|
2012-02-15 |
2015-12-18 |
Aileron Therapeutics, Inc. |
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
|
|
KR102112373B1
(ko)
|
2012-02-15 |
2020-05-18 |
에일러론 테라퓨틱스 인코포레이티드 |
펩티드모방체 마크로사이클
|
|
CN103308670B
(zh)
*
|
2012-03-08 |
2017-06-09 |
思芬构技术有限公司 |
用于预测对象患糖尿病和/或代谢综合征的风险的方法
|
|
CA2872314C
(en)
|
2012-05-03 |
2021-08-31 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
EA028929B1
(ru)
|
2012-05-03 |
2018-01-31 |
Зилэнд Фарма А/С |
Аналоги глюкагоноподобного пептида-2 (glp-2)
|
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
|
ES2602486T3
(es)
|
2012-06-21 |
2017-02-21 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran actividad de receptor de GIP
|
|
NZ704043A
(en)
|
2012-07-23 |
2017-07-28 |
Zealand Pharma As |
Glucagon analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
CN108383902A
(zh)
|
2012-09-26 |
2018-08-10 |
印第安纳大学研究及科技有限公司 |
胰岛素类似物二聚体
|
|
JP5715104B2
(ja)
*
|
2012-09-27 |
2015-05-07 |
アブビー インコーポレイティド |
治療的に活性なα−MSHアナログ
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
WO2014060606A1
(en)
|
2012-10-19 |
2014-04-24 |
Txp Pharma Gmbh |
Alpha- and gamma-msh analogues
|
|
WO2014071241A1
(en)
|
2012-11-01 |
2014-05-08 |
Aileron Therapeutics, Inc. |
Disubstituted amino acids and methods of preparation and use thereof
|
|
HUE035803T2
(en)
|
2012-12-21 |
2018-05-28 |
Sanofi Sa |
Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
|
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
|
JP6538645B2
(ja)
|
2013-03-14 |
2019-07-03 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
インスリン‐インクレチン複合物
|
|
US10052364B2
(en)
|
2013-03-15 |
2018-08-21 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
|
US10450343B2
(en)
|
2013-03-21 |
2019-10-22 |
Sanofi-Aventis Deutschland Gmbh |
Synthesis of cyclic imide containing peptide products
|
|
HUE034308T2
(en)
|
2013-03-21 |
2018-02-28 |
Sanofi Aventis Deutschland |
Preparation of hydantoin-containing peptide products
|
|
CA2911542C
(en)
*
|
2013-05-07 |
2022-06-07 |
Merck Patent Gmbh |
Peptides and peptide/active compound conjugates for renal targeting
|
|
US9988429B2
(en)
*
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
AR098065A1
(es)
|
2013-10-17 |
2016-04-27 |
Zealand Pharma As |
Análogos de glucagón acilados
|
|
US9763903B2
(en)
|
2013-10-22 |
2017-09-19 |
Steven Hoffman |
Compositions and methods for treating intestinal hyperpermeability
|
|
US10813901B2
(en)
|
2013-10-22 |
2020-10-27 |
Yamo Pharmaceuticals Llc |
Compositions and methods for treating autism
|
|
US9326962B2
(en)
|
2013-10-22 |
2016-05-03 |
Steven Hoffman |
Compositions and methods for treating intestinal hyperpermeability
|
|
US10751313B2
(en)
|
2013-10-22 |
2020-08-25 |
Yamo Pharmaceuticals Llc |
Compositions and methods for treating autism
|
|
US9585841B2
(en)
|
2013-10-22 |
2017-03-07 |
Tyme, Inc. |
Tyrosine derivatives and compositions comprising them
|
|
CA2929459C
(en)
|
2013-11-06 |
2022-05-03 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
AU2014345570B2
(en)
|
2013-11-06 |
2019-01-24 |
Zealand Pharma A/S |
Glucagon-GLP-1-GIP triple agonist compounds
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/升糖素受體促效劑
|
|
CA2932873A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized pharmaceutical formulations of insulin aspart
|
|
KR20160104726A
(ko)
|
2014-01-09 |
2016-09-05 |
사노피 |
인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
|
|
JP6641280B2
(ja)
|
2014-01-09 |
2020-02-05 |
サノフイSanofi |
インスリンアナログおよび/またはインスリン誘導体の安定化された医薬製剤
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
|
HUE052977T2
(hu)
*
|
2014-04-22 |
2021-06-28 |
Txp Pharma Gmbh |
Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
WO2016007873A1
(en)
|
2014-07-11 |
2016-01-14 |
The Regents Of The University Of Michigan |
Compositions and methods for treating craniosynostosis
|
|
BR112017005598A2
(pt)
|
2014-09-24 |
2017-12-12 |
Aileron Therapeutics Inc |
macrociclos peptidomiméticos e usos dos mesmos
|
|
CN108271356A
(zh)
|
2014-09-24 |
2018-07-10 |
印第安纳大学研究及科技有限公司 |
肠降血糖素-胰岛素缀合物
|
|
EP3197912B1
(en)
|
2014-09-24 |
2023-01-04 |
Indiana University Research & Technology Corporation |
Lipidated amide-based insulin prodrugs
|
|
EP3212218B1
(en)
|
2014-10-29 |
2021-06-30 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
|
WO2016081728A1
(en)
|
2014-11-19 |
2016-05-26 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
|
JP6787894B2
(ja)
|
2014-12-05 |
2020-11-18 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
組換えアルカリホスファターゼを用いた発作の処置
|
|
CN107206058A
(zh)
|
2014-12-12 |
2017-09-26 |
赛诺菲-安万特德国有限公司 |
甘精胰岛素/利西拉来固定比率配制剂
|
|
PL3242676T3
(pl)
|
2015-01-07 |
2024-07-15 |
Tonix Pharma Limited |
Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
|
|
CA2973883A1
(en)
|
2015-01-28 |
2016-08-04 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
|
WO2016154058A1
(en)
|
2015-03-20 |
2016-09-29 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
PL3283507T3
(pl)
|
2015-04-16 |
2020-05-18 |
Zealand Pharma A/S |
Acylowany analog glukagonu
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
|
|
JP6993961B2
(ja)
|
2015-08-17 |
2022-01-14 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
アルカリホスファターゼの製造
|
|
EP3355904A4
(en)
|
2015-09-28 |
2019-06-12 |
Alexion Pharmaceuticals, Inc. |
IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
|
|
WO2017068020A1
(en)
|
2015-10-20 |
2017-04-27 |
Txp Pharma Gmbh |
W-peptide analog
|
|
EP3368062A4
(en)
|
2015-10-30 |
2019-07-03 |
Alexion Pharmaceuticals, Inc. |
METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
|
|
US11065306B2
(en)
|
2016-03-08 |
2021-07-20 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
|
KR20180125979A
(ko)
|
2016-04-01 |
2018-11-26 |
알렉시온 파마슈티칼스, 인코포레이티드 |
알칼리성 포스파타아제로 근육 약화의 치료
|
|
US10898549B2
(en)
|
2016-04-01 |
2021-01-26 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
|
HRP20250215T1
(hr)
|
2016-04-12 |
2025-06-20 |
Tonix Pharma Limited |
Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
|
|
WO2017214130A1
(en)
|
2016-06-06 |
2017-12-14 |
Alexion Pharmaceuticals, Inc. |
Metal impact on manufacturing of alkaline phosphatases
|
|
JP7018933B2
(ja)
|
2016-08-18 |
2022-02-14 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
気管気管支軟化症の治療方法
|
|
IL266977B2
(en)
*
|
2016-11-30 |
2024-01-01 |
Purdue Research Foundation |
Fracture-targeted bone regeneration using thyroid hormone receptor stimulation
|
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
|
KR20190129058A
(ko)
|
2017-03-31 |
2019-11-19 |
알렉시온 파마슈티칼스, 인코포레이티드 |
성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
|
|
IL271245B2
(en)
|
2017-06-16 |
2023-10-01 |
Zealand Pharma As |
Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
|
|
JP7046990B2
(ja)
*
|
2017-06-29 |
2022-04-04 |
ユレカ・ソシエテ・ア・レスポンサビリテ・リミテ |
医薬的特性が改善されたプロドラッグペプチド
|
|
CN107964047B
(zh)
*
|
2017-12-18 |
2018-11-02 |
哈尔滨工业大学 |
基于内吗啡肽-1和神经降压素(8-13)的嵌合肽及其合成方法和应用
|
|
WO2019190752A1
(en)
|
2018-03-30 |
2019-10-03 |
Alexion Pharmaceuticals, Inc. |
Manufacturing of glycoproteins
|
|
JP2021530568A
(ja)
|
2018-07-19 |
2021-11-11 |
ヤモ・ファーマシューティカルズ・エルエルシー |
自閉症を処置するための組成物および方法
|
|
WO2020033867A2
(en)
|
2018-08-10 |
2020-02-13 |
Alexion Pharmaceuticals, Inc. |
Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
|
|
CN109879935B
(zh)
*
|
2019-03-04 |
2020-11-20 |
南京工业大学 |
一种多肽的液相合成方法
|
|
CA3161266A1
(en)
|
2019-12-09 |
2021-06-17 |
Alexion Pharmaceuticals, Inc. |
Alkaline phosphatase polypeptides and methods of use thereof
|
|
BR112023002608A2
(pt)
|
2020-08-12 |
2023-05-09 |
Txp Pharma Ag |
Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade
|
|
US12611447B2
(en)
|
2020-09-04 |
2026-04-28 |
Alexion Pharmaceuticals, Inc. |
Methods for treating bone mineralization disorders
|
|
AU2022218782B2
(en)
|
2021-02-12 |
2026-06-25 |
Alexion Pharmaceuticals, Inc. |
Alkaline phosphatase polypeptides and methods of use thereof
|
|
CN116284329B
(zh)
*
|
2023-04-28 |
2023-12-08 |
成都奥达生物科技有限公司 |
一种长效利钠肽化合物
|
|
CN116284221A
(zh)
*
|
2023-05-10 |
2023-06-23 |
安徽省华信生物药业股份有限公司 |
一种促肿瘤相关巨噬细胞向m1型极化的硒酵母活性肽及制备方法
|
|
WO2025196129A1
(en)
|
2024-03-19 |
2025-09-25 |
Epoqe Pharma Aps |
Calcitonin gene-related peptide analogues
|
|
CN120424236A
(zh)
*
|
2025-07-04 |
2025-08-05 |
南开大学 |
一种具有igf-1功能的自组装多肽及其生发应用
|